Financial HealthMilestone Scientific ended with $2.2 million in cash and no debt, indicating strong financial health.
Market ExpansionThe company plans to seek reimbursement from private payors, expanding the total available market to nine million procedures.
Technology AdvantageMilestone Scientific's proprietary, computer-controlled injection system for epidural steroid injections is being introduced into the pain management market, offering an attractive value proposition.